The company clocked a 4% increase in net profit, which stood at ₹4.53 crore for Q2 of the ongoing financial year. This ...

Aditya Birla Capital recorded revenue from operations at Rs 9381.35 crore, up 9.28 per cent as against Rs 8584.50 crore ...

A significant chunk of revenue for most Indian generic drugmaker comes from the U.S. and fierce competition in the North ...

In the corresponding quarter of the previous fiscal, Alembic Pharmaceuticals posted a net profit of ₹180.4 crore. The company ...

Indian drugmaker Alembic Pharmaceuticals reported a lower third-quarter profit on Monday, weighed down by weak local sales of its drugs that treat acute illnesses.

India's Divi's Laboratories reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses on customised production of chemical compounds used in ...

Drug firm Divi's Laboratories on Monday said its profit after tax (PAT) increased 65 per cent to Rs 589 crore for the ...

Despite Reddit's strong fundamentals and network effects, valuation appears 50% too high. Learn why RDDT stock is a Sell.

The stocks of the companies announcing Q3 results will be kept under active watch. Notably, markets have been seeing a ...

MercadoLibre has robust growth with significant ad revenue gains. See why MELI stock's high P/E ratio is justified, and why ...

The company's revenue from operations jumped 25 percent year-on-year to Rs 2,319 crore during the quarter under review.

Today, companies including Religare Enterprises, Gland Pharma, Fortis Malar Hospitals, Aditya Birla Capital, Alembic Pharma, ...